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TO THE EDITOR
Epidermolysis bullosa acquisita (EBA) is
a prototypic organ-specific autoimmune
disease, which is characterized by
chronic mucocutaneous subepidermal
blistering (Gupta et al., 2012; Schmidt
and Zillikens, 2013). The autoimmune
response is directed against a 290-kDa
protein located at the dermal–epidermal
junction (DEJ), which has been identi-
fied as the type VII collagen (Woodley
et al., 1988). Despite major achieve-
ments in the understanding of EBA
pathogenesis (Gupta et al., 2012),
therapy of EBA patients remains diffi-
cult, and, because of the low incidence
of the disease, data from clinical trials
are still missing. Most commonly corti-
costeroids in combination with other
(immunosuppressive) drugs are used
(Engineer and Ahmed, 2001), which is
associated with severe and potentially
life-threatening adverse reactions.
Therefore, there is a great and so far
unmet medical need for effective and
safe treatment options in EBA.
We have recently established a
mouse model of EBA induced by immu-
nization with an immunodominant
domain located within the non-collage-
nous 1 domain of murine type VII
collagen (Iwata et al., 2013). Induction
of skin blistering in experimental EBA
depends on the expression of activating
Fc gamma receptor (FcgR; Kasperkiewicz
et al., 2012). The detrimental contribu-
tion of FcgR binding to tissue-deposited
immune complexes (ICs) has been well
documented in models of autoantibody-
mediated diseases, such as rheumatoid
arthritis (Kleinau et al., 2000), immune-
mediated thrombocytopenia (McKenzie
et al., 1999), and autoimmune bullous
dermatoses (Ludwig et al., 2013). On the
basis of these findings, FcgR seems to
be a promising therapeutic target for
the treatment of autoantibody-mediated
inflammatory diseases. Currently, several
novel compounds targeting the interac-
tion of ICs with FcgR are pursued either
in preclinical model systems or in
clinical trials. Notably, pharmacological
modifications of IgG glycosylation at the
Fc fragment, which alters IgG’s affinity to
FcgR, have prophylactic and therapeutic
effects in several models of auto-
immunity (Collin and Ehlers, 2013).
Other potentially promising FcgR
targeting strategies, such as competitive
binding of ICs by recombinant soluble
FcgR2B (soluble CD32, sCD32, and
SM101) in idiopathic thrombocytopenia
or systemic lupus erythematosus, are
already evaluated in phase I/II clinical
trials (http://www.controlled-trials.com/
isrctn/search.html?srch=SM101).
Here, we evaluated whether treat-
ment with sCD32 has therapeutic effects
in experimental EBA. sCD32 binds to IC
and thereby blocks the binding of FcgR
expressed on the surface of immune
cells. Eventually, effector cells cannot
be activated via FcgR (Ierino et al.,
1993).
First, we investigated the effect of
sCD32 on activating FcgR-dependent
reactive oxygen species (ROS) release
from IC-activated neutrophils (Supple-
mentary Materials and Methods online).
sCD32 inhibited IC-induced neutrophil
ROS production in a dose-dependent
manner (Figure 1a). In detail, compared
with positive control, 0.01, 0.1, and
0.5 mg ml1 sCD32 significantly reduced
ROS production by 30, 65, and 75%,
respectively. Next, we tested whether
sCD32 could hinder dermal–epidermal
separation in an ex vivo model of auto-
immune bullous dermatoses. Accord-
ingly, in the presence of leukocytes,
sCD32 successfully impaired FcgR-
dependent dermal–epidermal separa-
tion on cryosections of human skin
incubated with sera containing patho-
genic antibodies against DEJ structures
(Figure 1b and c; Supplementary
Materials and Methods online). To
validate this ex vivo inhibitory activity
of sCD32 on antibody-induced tissue
injury in vivo, we next induced experi-
mental EBA in mice by immunization
with vWFA2 (Supplementary Materials
and Methods online). After immuniza-
tion, mice were allocated to sCD32 or
phosphate-buffered saline (PBS) treat-
ment if individual mice had 2% or more
of their body-surface area affected by
skin lesions (Supplementary Materials
and Methods online). Compared with
PBS-injected mice, sCD32 treatment led
to a significantly lower clinical disease
severity (Figure 2a, left, *Po0.05, t-test).
At inclusion to treatment (week 0),
average disease scores were not differ-
ent between the groups (3.4±0.21%
and 3.4±0.20%) of affected body-sur-
face area in PBS and sCD32 treatment,
respectively. Cumulative disease sever-
ity expressed as area under the curve
during the entire observation period was
also significantly lower in sCD32-trea-
ted mice as compared with PBS
control mice (Figure 2a, right,
P¼0.031, t-test). At the end of the 4-
week treatment period, PBS-treated
mice showed diffuse erythema and
crusts on the ear and tail, and hair loss
around the eyes (Figure 2b, left). In
contrast, less erythema on the ear and
no disease on tail or around the eyes in
mice treated with sCD32 were observed
(Figure 2b, right). Histologically, mice
treated with sCD32 showed a signifi-
cant decrease in the dermal leukocyte
infiltration, compared with PBS-treated
mice (Po0.05, Figure 2c). sCD32 treat-
ment also led to an B20% reduction in
circulating antigen-specific autoantibo-
dies compared with PBS-treated mice
(Figures 2d, P¼ 0.048; t-test), whereas
total IgG levels were not significantly
different (data not shown). At the sameAccepted article preview online 20 October 2014; published online 13 November 2014
Abbreviations: EBA, epidermolysis bullosa acquisita; DEJ, dermal–epidermal junction; FcgR, Fc gamma
receptor; IC, immune complex; PBS, phosphate-buffered saline; ROS, reactive oxygen species
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time point, all mice showed similar IgG
deposits at DEJ as determined by direct
immunofluorescence (Figure 2e, upper).
Representative pictures of direct immu-
nofluorescence show IgG deposits at DEJ
(Figure 2e, down). This discrepancy
between circulating and tissue bound
autoantibodies may be because of their
different half-lives.
sCD32 treatment has also demon-
strated beneficial effects in models of
other autoantibody-mediated diseases,
such as nephritis in lupus-prone NZB/
NZW F(1) hybrid mice (Werwitzke
et al., 2008) and joint inflammation in
collagen-induced arthritis (Magnusson
et al., 2008). On the basis of our
observations ex vivo and in vivo, the
therapeutic effect of sCD32 can be
attributed to both direct and indirect
mechanisms, which mean the inhibi-
tion of neutrophil function and auto-
antibody production, respectively. On
the basis of our observation of thera-
peutic efficacy in experimental EBA, it
is tempting to speculate that sCD32
binds to the in situ deposited ICs. This
assumption, however, needs further
experimental exploration. Regarding
the effect on autoantibody production,
controversial results have been reported.
In the lupus-prone NZM/NZW mouse
model neither prophylactic nor thera-
peutic treatment with sCD32 affected
anti-double stranded DNA serum titers
(Werwitzke et al., 2008). In contrast,
sCD32 suppressed secondary and
primary in vitro antibody responses
(Varin et al., 1989) and caused a
temporary decrease in collagen-specific
autoantibodies in CIA (Magnusson et al.,
2008). In support of these later obser-
vations, we here report a sustained
reduction of antigen-specific but not of
total circulating IgG in immunization-
induced EBA. This effect may be
mediated through a blockade of the
IgG2a-mediated enhancement of anti-
body and T-cell responses via increased
antigen presentation to CD4þ T cells
by FcgR-expressing antigen-presenting
cells (Getahun et al., 2004).
Taken together, our findings provide
evidence for a beneficial role of sCD32
in experimental EBA. As this model
mostly reflects the inflammatory variant
of EBA, our findings may pave the way
for its clinical application in patients
with autoimmune bullous dermatoses,
where disease manifestation depends on
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Figure 1. sCD32 inhibits neutrophil activation ex vivo by immune complexes (IC). (a) IC were generated by incubation of human IgG on 96-well plates. After
washing, human neutrophils were added in the presence or absence of sCD32. Neutrophil activation was assayed by measuring reactive oxygen species (ROS)
production. sCD32 inhibited ROS production from IC-activated neutrophils in a dose-dependent manner. Data are based on five experiments, using different
leukocyte donors, per group (*Po0.05, analysis of variance (ANOVA)), and expressed as mean±SEM. (b) Cryosections from normal human skin were incubated
with sera from bullous pemphigoid (BP) patients. Subsequently, leukocytes from healthy blood donors were added. This induced dermal–epidermal separation in
the absence of sCD32. In the presence of sCD32, autoantibody-induced, leukocyte-dependent dermal–epidermal separation was significantly impaired. Data are
based on 21 experiments, that is, different BP sera and leukocyte donors, per group (*Po0.05 vs. positive control, ANOVA), and expressed as mean±SEM. (c)
Similar results were obtained when incubating normal human skin with epidermolysis bullosa acquisita (EBA) patient IgG (n¼1) and leukocytes from healthy
blood donors (n¼5). In all sections incubated with EBA patient IgG, dermal–epidermal separation was induced; in contrast to the experiments using BP sera, a
wider variation was observed (ranging from 2% to 100%). Therefore, data were normalized to the dermal–epidermal separation of the positive control (set at
100%). Simialar to experiments using BP patient serum, sCD32 also impaired dermal–epidermal separation induced by EBA serum. Compared with positive EBA
control serum, dermal–epidermal separation was reduced to 61±6% in sCD32-treated sections (concentration: 0.5mg ml 1; Po0.001, t-test). A representative
example of each treatment group from a total of five experiments is demonstrated. Asterisks indicate the position of dermal–epidermal junction without any
separation, and arrows indicate areas of dermal–epidermal separation. Bar¼ 200mm.
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an interaction of ICs with effector mye-
loid cells.
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Figure 2. sCD32 suppresses progression of already established experimental epidermolysis bullosa acquisita (EBA). (a) Arrow at week 0 indicates starting point of
treatment (left). Compared with phosphate-buffered saline (PBS)-injected mice, sCD32 treatment led to significantly fewer skin lesions. Data are based on total 13
mice per group (left, *Po0.05, t-test), and expressed as mean±SEM. Overall, clinical disease severity (area under the curve (AUC)) was lower in mice treated with
sCD32 (right, P¼ 0.031, t-test). (b) Representative clinical pictures 4 weeks after allocation to PBS (left) or sCD32 treatment (right). (c) The score of dermal infiltrates
was significantly lower in mice treated with sCD32 (Po0.05, t-test). Representative hematoxylin and eosin (H&E)-stained sections of skin from mice treated with
sCD32 (right) or PBS (left) are shown. Numbers in upper right corners indicate the mean±SEM of the semiquantitative scored infiltration, ranging from 0 (no
infiltration) to 3 (severe dermal infiltration). Bar¼200mm. (d) Mice treated with sCD32 hadB20% less autoantibodies compared with control (P¼ 0.048; t-test).
(e) The fluorescence intensity of IgG was not different. Representative pictures of IgG deposits. Bar¼50mm.
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TO THE EDITOR
Alopecia areata (AA) is a common human
hair loss disorder that affects both sexes
and all age groups. Although the precise
etiopathogenesis of AA remains unknown,
immunological and genetic association
studies have implicated both innate and
acquired immunity. Previous genetic
research has identified several susceptibil-
ity factors. These comprise genes that are
assumed to be involved in inflammation
and in the regulation of T cells or other
forms of immune modulation (Petukhova
et al., 2010; John et al., 2011; Jagielska
et al., 2012), genes in the histo-
compatibility leukocyte antigen (HLA)–
encoding region (Entz et al., 2006;
Petukhova et al., 2010), and various
cytokine genes (Petukhova et al., 2010;
Jagielska et al., 2012; Redler et al., 2012).
To characterize the immune-related
nature of AA further, we used the
Immunochip to analyze a large and
clinically well-characterized sample of
767 AA patients and 1,475 controls of
Central-European origin and then fol-
lowed up the most strongly associated
variants in an independent Central-Eur-
opean sample of 1,016 cases and 1,060
controls (Supplementary Materials and
Methods online). The Immunochip is a
unique custom-based Illumina Bead-
Chip array (Illumina, San Diego, CA)
that enables dense mapping of a large
number of susceptibility loci and risk
variants for immune-mediated disease
(Trynka et al., 2011).
Ethical approval was obtained from
the appropriate ethics committees, and
all participants provided written informed
consent prior to blood sampling.
Following stringent quality control of
the discovery Immunochip data (Supple-
mentary Materials and Methods online),
the strongest associations were observed
for variants of the major histocompa-
tibility complex (MHC) class II DQ beta
1 (HLA-DQB1) and class II DQ alpha 2
(HLA-DQA2), with P-values ranging
from 5.591015 to 1.71 10 19.
Our discovery step also provided sup-
port for a large number of additional
regions of interest that did not pass the
threshold of genome-wide significance
but which did reach nominal signifi-
cance (Supplementary Table S3 online).
To follow up the results of the
discovery step, we first performed a
targeted analysis of the HLA-region. This
involved imputation using SNP2HLA
and a stepwise logistic regression
analysis (Supplementary Material and
Methods online). This approach gener-
ated genome-wide/region-wide signifi-
cant results for three independent HLA-
DQB1 variants (rs9275208: Puncorr.¼
1.7110 19, Pcorr.¼2.1 10 14; sin-
gle-nucleotide polymorphism (SNP)
DQB1_32742309_Cx: Puncorr.¼5.02
 108, Pcorr.¼ 4.25 10 4; HLA_
DQB1_0503: Puncorr.¼5.36108,
Pcorr.¼4.35104). In addition,
genome-wide/region-wide significant
results were obtained for variants of
three further HLA-loci (HLA-DQA2,
HLA-C, and HLA-DRB1; Supplemen-
tary Table S1 online). However, these
three association signals were probably
dependent on the detected HLA-DQB1
association signals.
In a subsequent step, the 35 most
strongly associated susceptibility var-
iants outside the HLA region were
followed up in our independent case-
control sample. These variants were
selected by choosing a maximum
of two SNPs from all regions with
nominal significance in the discovery step
(Supplementary Materials and Methods
online). Three of these 35 genotyped
variants (rs4916209, rs11904361, and
rs10798176) were replicated with
nominal significance (Table 1). To
obtain robust evidence for association,
we performed a meta-analysis of the
data from the discovery and follow-up
cohorts. In this analysis, all three repli-
cated variants failed to surpass the
threshold of genome-wide significance
but reached nominal significance as
follows (Table 1): (i) Tumor necrosis
factor (TNF; ligand) superfamily,
member 4 (TNFSF4) variant rs4916209:
Pcomb.¼ 6.8510 07; (ii) Thyroid
adenoma associated (THADA) variantAccepted article preview online 22 October 2014; published online 13 November 2014
Abbreviations: AA, alopecia areata; FASLG, Fas ligand (TNF superfamily, member 6); GWA, genome-wide
association; HLA-DQA2, MHC class II DQ alpha 2; HLA-DQB, MHC class II DQ beta; KIAA0350/
CLEC16A, C-type lectin domain family 16, member A; MHC, major histocompatibility complex; OX40L,
OX40 ligand; THADA, thyroid adenoma associated; TNF, tumor necrosis factor; TNFSF4, TNF (ligand)
superfamily, member 4
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